Similarly, the analysis of Hellmann et al. showed that the first line treatment with nivolumab-ipilimumab provided clinical benefits for patients with NSCLC with a high TMB (≥10 mutations per mega base), regardless of their tumor PD-L1 expression levels (44). Here, CD274 is linked to neoplasm.